Back to results
US 2022/0033507 A1Published application
Bispecific antibody targeting il-1r1 and nlpr3
AssigneeUniversity of Ulster
InventorVictoria McGILLIGAN
Life of this patent
Estimating the term…
Abstract
The present disclosure concerns modulators of the NLRP3 inflammasome pathway, in particular an NLRP3 inflammasome modulator which is capable of binding to both of IL-IR1 and NLRP3.
Claims25
An NLRP3 inflammasome modulator that binds to one or more of IL-1 R1 and NLRP3.
(canceled)
(canceled)
Dependencies are inferred from the claim text.